$Recursion Pharmaceuticals, In

Recursion Pharmaceuticals (RXRX) is currently undervalued.

With analysts like Needham targeting $8.00. and ~$533M in cash and partnerships with Roche, Sanofi, and Bayer, RXRX is well-capitalized to fund its AI-driven drug discovery pipeline. Together with REC-4881 being a potential near-term catalyst and asset, RXRX is undervalued at below $5.

If revenue accelerates to $200M+ over 2–3 years and clinical programs (like REC-617) progress, RXRX could command EV/revenue multiples of 8–10x, supporting a $7–10/share valuation.

The recent Exscientia acquisition strengthens their AI stack and expands opportunity. High risk, high reward — but if the pipeline delivers, the upside is compelling. This is a long-term biotech play with transformative AI potential.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":479305002385440,"tweetId":"479305002385440","gmtCreate":1758044636084,"gmtModify":1758061423181,"author":{"id":3576143479038940,"idStr":"3576143479038940","authorId":3576143479038940,"authorIdStr":"3576143479038940","name":"Mike Yong","avatar":"https://community-static.tradeup.com/news/af67eb1674939c91d407718f5b29ebea","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.23","exceedPercentage":"93.64%","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":12,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><a href=\"https://ttm.financial/S/RXRX\">$Recursion Pharmaceuticals, Inc.(RXRX)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;\n \nRecursion Pharmaceuticals (RXRX) is currently undervalued.\n \nWith&nbsp;analysts like Needham targeting $8.00. and&nbsp;~$533M in cash and partnerships with Roche, Sanofi, and Bayer, RXRX is well-capitalized to fund its AI-driven drug discovery pipeline. Together with REC-4881 being a potential near-term catalyst and asset, RXRX is undervalued at below $5.\nIf revenue accelerates to $200M+ over 2–3 years and clinical programs (like REC-617) progress, RXRX could command EV/revenue multiples of 8–10x, supporting a $7–10/share valuation.&nbsp;\nThe recent Exscientia acquisition strengthens their AI stack and expands opportunity. High risk, high reward — but if the pipeline delivers, the upside is compelling. This is a long-term biotech play with transformative AI potential.\n\n </body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/RXRX\">$Recursion Pharmaceuticals, Inc.(RXRX)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;\n \nRecursion Pharmaceuticals (RXRX) is currently undervalued.\n \nWith&nbsp;analysts like Needham targeting $8.00. and&nbsp;~$533M in cash and partnerships with Roche, Sanofi, and Bayer, RXRX is well-capitalized to fund its AI-driven drug discovery pipeline. Together with REC-4881 being a potential near-term catalyst and asset, RXRX is undervalued at below $5.\nIf revenue accelerates to $200M+ over 2–3 years and clinical programs (like REC-617) progress, RXRX could command EV/revenue multiples of 8–10x, supporting a $7–10/share valuation.&nbsp;\nThe recent Exscientia acquisition strengthens their AI stack and expands opportunity. High risk, high reward — but if the pipeline delivers, the upside is compelling. This is a long-term biotech play with transformative AI potential.\n\n </body></html>","text":"$Recursion Pharmaceuticals, Inc.(RXRX)$ Recursion Pharmaceuticals (RXRX) is currently undervalued. With analysts like Needham targeting $8.00. and ~$533M in cash and partnerships with Roche, Sanofi, and Bayer, RXRX is well-capitalized to fund its AI-driven drug discovery pipeline. Together with REC-4881 being a potential near-term catalyst and asset, RXRX is undervalued at below $5. If revenue accelerates to $200M+ over 2–3 years and clinical programs (like REC-617) progress, RXRX could command EV/revenue multiples of 8–10x, supporting a $7–10/share valuation. The recent Exscientia acquisition strengthens their AI stack and expands opportunity. High risk, high reward — but if the pipeline delivers, the upside is compelling. This is a long-term biotech play with transformative AI potential.","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/479305002385440","repostId":0,"isVote":1,"tweetType":1,"viewCount":425,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["RXRX"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":689,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/479305002385440"}